Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE vs AMOXICILLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.
Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Moderate to severe pain relief; combinations are used to reduce abuse potential.
Upper respiratory tract infections (e.g., otitis media, sinusitis, pharyngitis/tonsillitis),Lower respiratory tract infections (e.g., community-acquired pneumonia, acute exacerbation of chronic bronchitis),Genitourinary tract infections (e.g., cystitis, urethritis),Skin and skin structure infections,Helicobacter pylori eradication (in combination with clarithromycin and a proton pump inhibitor),Lyme disease (early localized),Prophylaxis of infective endocarditis (for dental procedures in high-risk patients),Off-label: Anthrax (post-exposure prophylaxis), uncomplicated gonorrhea
Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 1 g orally every 8 hours.
Pentazocine has an elimination half-life of 2-3 hours in healthy adults, which may be prolonged in patients with hepatic impairment. Naloxone has a terminal half-life of 0.5-1.5 hours in adults, with a rapid decline in plasma levels; the short half-life limits its duration of opioid antagonism.
Terminal elimination half-life: 1-1.5 hours in normal renal function. Prolonged to 7-20 hours in end-stage renal disease.
Pentazocine is metabolized primarily by hepatic conjugation (glucuronidation) and oxidation via CYP2C19 and CYP2D6; naloxone is extensively metabolized by the liver, primarily via glucuronidation (UGT2B7).
Amoxicillin is primarily metabolized by hydrolysis to penicilloic acid (inactive). It is not extensively metabolized by the liver; about 60% of an oral dose is excreted unchanged in urine.
Pentazocine is primarily metabolized in the liver and excreted in urine as conjugates of glucuronide and sulfate, with about 60% of a dose excreted renally within 24 hours as metabolites and unchanged drug (less than 5% unchanged). Naloxone undergoes extensive hepatic metabolism to naloxone-3-glucuronide, which is excreted renally; approximately 50% of a dose is excreted as conjugates in urine within 6 hours.
Renal: 60-80% unchanged via glomerular filtration and tubular secretion. Biliary: up to 20% excreted in bile. Fecal: minimal.
Pentazocine: Approximately 35-65% bound to plasma proteins (mainly albumin). Naloxone: Approximately 32-45% bound to plasma proteins (mainly albumin).
17-20% bound to serum albumin.
Pentazocine: Vd ~2-3 L/kg, indicating extensive tissue distribution. Naloxone: Vd ~2-3 L/kg, also indicating wide distribution.
0.3-0.4 L/kg. Distributes well into most body fluids and tissues, including pleural, peritoneal, and synovial fluids; limited CNS penetration unless meninges inflamed.
Oral pentazocine: 20-30% due to first-pass metabolism. Intramuscular pentazocine: 100%. Subcutaneous pentazocine: 100%. Oral naloxone: <2% due to extensive first-pass metabolism. Intramuscular and subcutaneous naloxone: 100%. Intravenous: 100% for both.
Oral: 74-92% (absorption is not food-dependent). IM: approximately 100%.
GFR 30-50 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Administer every 12 hours or consider alternative.
Cr Cl 30-50 m L/min: 250-500 mg every 8-12 hours. Cr Cl 10-29 m L/min: 250-500 mg every 12 hours. Cr Cl <10 m L/min: 250-500 mg every 24 hours. Hemodialysis: 250-500 mg every 24 hours, supplemented during and after dialysis.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend interval; Child-Pugh Class C: Avoid use.
No dose adjustment required for mild to moderate hepatic impairment. Severe hepatic impairment (Child-Pugh class C): use with caution; specific dosing guidelines not established.
Not recommended for children under 12 years. For older children (≥12 years): Pentazocine 50 mg (with naloxone 0.5 mg) orally every 3-4 hours as needed; maximum 6 tablets daily.
Children >3 months: 20-40 mg/kg/day divided every 8 hours for mild to moderate infections; 40-90 mg/kg/day divided every 8-12 hours for severe infections. Maximum 3 g/day.
Initiate with half the usual adult dose (one-half tablet) and titrate carefully due to increased sensitivity and risk of respiratory depression.
No specific dose adjustment; monitor renal function and adjust based on Cr Cl. Caution with concurrent nephrotoxic agents.
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of life-threatening respiratory depression when used with benzodiazepines or other CNS depressants.
No FDA black box warning.
Respiratory depression; hypotension; increased intracranial pressure; seizure risk (pentazocine); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; interaction with MAOIs; risk of dependence and withdrawal; gastrointestinal obstruction; impaired renal or hepatic function; head injury.
Hypersensitivity reactions including anaphylaxis have been reported; contraindicated in patients with known penicillin allergy.,Clostridium difficile-associated diarrhea (CDAD) may occur and must be considered in patients presenting with diarrhea after antibiotic use.,Serious skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) can occur; discontinue if rash or other allergic signs appear.,Use caution in patients with renal impairment; dosage adjustment may be necessary.,Prolonged use may result in superinfection with non-susceptible organisms.
Hypersensitivity to pentazocine or naloxone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; patients receiving MAOIs or within 14 days.
History of hypersensitivity reaction to any penicillin or beta-lactam antibiotic.,Infectious mononucleosis (increases risk of maculopapular rash).,Phenylketonuria (some formulations contain aspartame).
No specific food interactions are reported for this combination. However, grapefruit juice may theoretically affect metabolism via CYP3A4 (pentazocine is metabolized by CYP3A4), but clinical significance is unknown. Advise patients to maintain a consistent diet.
No significant food interactions. Absorption is not affected by food; may be taken with meals to reduce gastrointestinal upset. Avoid concurrent alcohol consumption as it may increase risk of side effects like nausea and vomiting.
Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Third trimester: Chronic use may cause fetal dependence; neonatal withdrawal syndrome reported. High doses near term may cause neonatal respiratory depression.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: no increased risk of major malformations observed in large cohort studies. Second and third trimesters: use only if clearly needed; no known fetal harm, but caution due to maternal physiological changes.
Pentazocine is excreted in breast milk in small amounts (estimated relative infant dose <3%). Naloxone is poorly bioavailable orally. Generally considered compatible with breastfeeding; monitor infant for sedation or poor feeding. M/P ratio for pentazocine is approximately 1.0.
Amoxicillin is excreted into breast milk in small amounts (M/P ratio approximately 0.014-0.015). Considered compatible with breastfeeding; potential for diarrhea or allergic sensitization in infant, but generally safe.
No established dose adjustments for pregnancy; however, pharmacokinetic changes (increased volume of distribution, enhanced clearance) may require higher or more frequent doses of pentazocine for adequate analgesia. Use lowest effective dose and shortest duration.
No dose adjustment required for amoxicillin in pregnancy; however, increased renal clearance and expanded plasma volume may lower serum concentrations. For severe infections, consider standard dosing with monitoring of clinical response.
Naloxone in this fixed-dose combination is included to deter opioid abuse by reversing euphoria. The pentazocine component is a mixed agonist-antagonist opioid; naloxone has poor oral bioavailability but becomes active parenterally, precipitating withdrawal in opioid-dependent individuals. Use with caution in patients with impaired renal or hepatic function. Monitor for respiratory depression, especially in opioid-naive patients, as pentazocine alone can cause respiratory depression.
For streptococcal pharyngitis, amoxicillin 50 mg/kg once daily (max 1 g) is as effective as multiple daily doses and improves adherence. In penicillin-allergic patients, the cross-reactivity risk with cephalosporins is low; a cephalosporin can be used if no history of immediate-type hypersensitivity. Amoxicillin is not effective against penicillinase-producing staphylococci or most Gram-negative organisms due to beta-lactamase production. Monitor for rash in patients with infectious mononucleosis (ampicillin rash occurs more frequently, but amoxicillin also has increased risk). Dose adjustment needed for creatinine clearance <30 m L/min.
Take exactly as prescribed; do not crush or inject tablets, as injected naloxone can cause severe withdrawal in opioid-dependent individuals.,This medication contains naloxone to discourage misuse; injection will cause withdrawal symptoms.,Report any signs of withdrawal (e.g., nausea, vomiting, sweating, agitation) or breathing difficulty.,Avoid alcohol and other central nervous system depressants as they increase risk of respiratory depression.,Do not use with other opioids unless directed, as effects are unpredictable.,Keep out of reach of children; accidental ingestion may cause severe respiratory depression.
Take exactly as prescribed; complete the full course even if you feel better.,Can be taken with or without food; if stomach upset occurs, take with a meal.,Swallow capsules whole; do not crush or chew; oral suspension shake well before each dose.,Skip missed dose if almost time for next; do not double dose.,Seek immediate medical help for signs of allergic reaction: hives, difficulty breathing, swelling of face/lips/tongue.,May cause diarrhea; contact doctor if watery or bloody stools.,Inform doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Avoid large amounts of grapefruit juice as it may affect absorption (limited clinical significance).
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
"Amoxicillin may reduce the metabolism of Indinavir via inhibition of CYP3A4, leading to increased plasma concentrations of Indinavir. This can elevate the risk of Indinavir-related toxicities such as nephrolithiasis, hepatotoxicity, and gastrointestinal intolerance. Patients may experience exacerbated adverse effects without a corresponding increase in antiviral efficacy."
"Amoxicillin may inhibit the CYP3A4-mediated metabolism of nicardipine, a calcium channel blocker, leading to increased plasma concentrations of nicardipine. This can potentiate vasodilation and negative chronotropic effects, resulting in an increased risk of hypotension, bradycardia, and peripheral edema. Patients, especially those with pre-existing cardiovascular conditions, should be monitored for enhanced antihypertensive effects and adverse reactions when these drugs are coadministered."
"Amoxicillin may inhibit the metabolism of bortezomib through competitive inhibition of cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, potentially leading to increased bortezomib exposure. This interaction could result in enhanced toxicity of bortezomib, including peripheral neuropathy, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of bortezomib toxicity when amoxicillin is coadministered, especially in patients with pre-existing hepatic impairment or other risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE vs AMOXICILLIN, answered by our medical review team.
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.. AMOXICILLIN is a Penicillin Antibiotic that works by Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE and AMOXICILLIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is: Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.. The standard adult dose of AMOXICILLIN is: 250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 1 g orally every 8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE and AMOXICILLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Thi. AMOXICILLIN is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: no increased risk of major malformations observed in large cohort studies. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.